Abiopharma

🔍 Beauvais Jason B (Executive)

Company: Main Street Capital CORP (MAIN)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 108 shares of Common Stock at $52.02 per share (Direct)
  Date: 2026-06-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 196,292.97 | transaction_form_type: 5 | Footnotes: F1
• Acquired 128 shares of Common Stock at $51.01 per share (Direct)
  Date: 2026-06-29 | Code: J | equity_swap_involved: 0 | shares_owned_after: 196,420.76 | transaction_form_type: 5 | Footnotes: F1
• Acquired 109 shares of Common Stock at $53.09 per share (Direct)
  Date: 2026-07-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 196,529.86 | transaction_form_type: 5 | Footnotes: F1

Footnotes:

• F1: The reporting person acquired these shares under a dividend reinvestment plan, pursuant to a dividend reinvestment transaction exempt from Section 16 under Rule 16a-11.